AOD-9604
NOT FDA APPROVEDMetabolic / fat-loss peptide
Also known as: hGH fragment 176-191
Not FDA approved as a drug. A fragment of human growth hormone, marketed as a fat-loss peptide.
Early evidence, mostly unproven in humans
- Regulatory standing. Sold as a research chemical, not approved
- Limited human data. Some human data exists, not conclusive
- No registered human trials. Nothing registered on ClinicalTrials.gov
- 1 cited source. Cited references provided
A read on the weight of evidence and regulatory standing behind this compound. It is not a safety score, not a purity or quality rating, and not medical advice. It is not a claim that this compound treats, cures, or prevents any condition, and not an endorsement or a recommendation to buy or use it. A low score means the evidence is thin — not that a product is unsafe; a high score means the evidence is strong — not that anyone should take it. PLOBT is independent and takes no money from any vendor; no company can pay to change this score.
Proven: early safety and metabolism studies exist, and it does not raise IGF-1 or blood sugar. NOT proven: meaningful fat loss in humans. The marketed 'targeted fat burner' claims outrun the actual human efficacy data.
What it is
A modified fragment of the hGH molecule proposed to stimulate fat breakdown (lipolysis) without the growth-hormone effects on IGF-1 or blood sugar.
What the research says
Early-stage human studies showed some positive activity on fat metabolism and a reassuring safety profile, but did not establish reliable clinical weight loss.
Published literature
Live from Europe PMC. Peer-reviewed papers discussing AOD-9604 in their title or abstract, most-cited first. This is how much has been published — not how much is proven in humans. It counts landmark trials, animal studies and reviews alike.
Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls.
Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.
Obesity drugs in clinical development.
Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions.
Registered human trials
Live from ClinicalTrials.gov, the US NIH registry of human studies, refreshed daily. Counts studies where AOD-9604 is the intervention being tested.
No interventional studies for AOD-9604 are registered on ClinicalTrials.gov. That is not proof it is unsafe or useless, but it means the human evidence here does not come from registered clinical trials, the exact gap the marketing tends to hide.
FDA recalls & enforcement
AOD-9604 has no FDA recall or drug record at all — because it is not an FDA-regulated drug. That absence is not a safety signal. It means this compound is sold outside the system that inspects, tracks and recalls unsafe products in the first place.
Source: openFDA drug enforcement.
What people log it for
Descriptive, based on what users track. Not an endorsement or a suggested use.
Risks & unknowns
- Human efficacy for weight loss is not established.
- Gray-market purity varies.
Doses reported in studies & protocols
No established clinical dose. This is not a recommendation.
Purity reality
Verify content with a third-party COA before trusting a label.
None yet. PLOBT does not publish invented purity numbers. Real third-party COA data, mapped to vendor and batch, is in development — and it is the one thing we refuse to fake.
Sources
We cite peer-reviewed journals, PubMed/PMC, FDA and university sources, not vendor marketing.